NovoCure Stock In Focus After Revenue Guidance Raise And Quarterly Sales Update

Simply Wall St.11-06

NovoCure raised its 2026 total net revenue outlook to a range of US$736 million to US$743 million and reported third quarter 2026 sales of US$193.4 million, with the quarterly net loss narrowing to US...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment